Cypress Semiconductor (NASDAQ:CY) Exceeds Expectations In Terms of Plan for Cost Synergies from Spansion Merger- Accenture plc (NYSE:ACN)

Cypress Semiconductor Corporation (NASDAQ:CY) kept active in under and overvalue discussion, CY holds price to book ratio of 2.16 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

Cypress president and chief executive officer, Hassane El-Khoury recently said that they are pleased to report a strong fourth quarter and full year for Cypress in 2016. They grew firm, improved their gross margin, exceeded their expectations in terms of their plan for cost synergies from the Spansion merger and changed the strategic direction of the company, fully implementing Cypress 3.0, our blueprint for selling complete embedded solutions into markets growing faster than the broader semiconductor industry.

The firm has price volatility of 2.72% for a week and 2.73% for a month. Its beta stands at 1.86 times. Narrow down four to firm performance, its weekly performance was 5.07% and monthly performance was 10.48%.

Accenture plc (NYSE:ACN) runs in leading trade, it are moving down -0.42% to trade at $115.43. ACN attains analyst recommendation of 2.30 on scale of 1-5 with week’s performance of 1.96%.

To find out the technical position of ACN, it holds price to book ratio of 9.68 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 18.04, and price to earnings ratio calculated as 17.09. The price to earnings growth ration calculated as 1.71. ACN is presenting price to cash flow of 18.25 and free cash flow concluded as 23.05.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 35.40%, and looking further price to next year’s EPS is 9.01%. While take a short look on price to sales ratio, that was 2.11 and price to earning ration of 17.09 attracting passive investors.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *